Chemical formula: C₁₆H₂₂N₂O₃ Molecular mass: 290.163 g/mol PubChem compound: 4916
Procaterol interacts in the following cases:
| Drugs | Signs, Symptoms, and Treatment | Mechanism and Risk Factors |
|---|---|---|
| Corticosteroids (e.g. betamethasone, prednisolone and hydrocortisone sodium succinate) and Diuretics (e.g. Furosemide) | The combined use of this drug with corticosteroids and diuretics may cause a decrease in serum potassium levels, resulting in arrhythmias. If any of these abnormalities are observed, appropriate measures such as dose reduction or discontinuation of the treatment should be taken. | Corticosteroids and diuretics augment the excretion of potassium from renal tubules, possibly resulting in an excessive decrease in serum potassium levels. |
| Drugs | Signs, Symptoms, and Treatment | Mechanism and Risk Factors |
|---|---|---|
| Catecholamines (e.g. adrenaline and isoproterenol) | The combined use of this drug with catecholamines may cause arrhythmias or, in some cases, cardiac arrest. | Adrenaline, isoproterenol and other catecholamines potentiate adrenoreceptor stimulating action of this drug. possibly resulting in the induction of arrhythmias |
| Drugs | Signs, Symptoms, and Treatment | Mechanism and Risk Factors |
|---|---|---|
| Xanthine derivatives (e.g. theophylline aminophylline hydrate and diprophylline) | The combined use of this drug with xanthine derivatives may aggravate hypokalemia and cardiovascular adverse reactions (e.g. tachycardia, arrhythmias ) due to β- adrenergic stimulation. If any of these abnormalities are observed, the dose should be reduced or treatment should be discontinued immediately | Xanthine derivatives potentiate adrenoreceptor stimulating action of this drug, possibly resulting in a decrease in serum potassium levels and aggravating cardiovascular adverse reactions. The mechanism responsible for induction of hypokalemia is not known |
Procaterol should be administered with care in patients with hyperthyroidism. The disease may be exacerbated.
Procaterol should be administered with care in patients with hypertension. Blood pressure may further increase.
Procaterol should be administered with care in patients with heart disease. Palpitation, arrhythmia, exacerbation of heart disease, and other symptoms may occur.
Procaterol should be administered with care in patients with diabetes mellitus. The disease may be exacerbated.
This drug should be administered to pregnant or possibly pregnant women only if the expected therapeutic benefit is thought to outweigh any possible risk. (The safety of this drug during pregnancy has not been established.)
Nursing should be interrupted before starting treatment with the drug. (Rat studies showed that procaterol hydrochloride hydrate is excreted in the breast milk.)
In clinical trials involving 22,757 subjects, a total of 644 patients (2.83%) showed adverse reactions including abnormal laboratory values. The following summary of data includes adverse reactions reported after marketing without data on the incidence.
1) Shock, anaphylaxis: Shock or anaphylaxis may occur. Patients should therefore be closely monitored. If abnormal findings are observed, the drug should be discontinued and appropriate measures taken.
2) Significant decreases in serum potassium levels have been reported in patients receiving procaterol hydrochloride hydrate. If xanthine derivatives, corticosteroids, or diuretics are coadministered with this drug in patients with severe asthma, extreme care is necessary to minimize the possibility of aggravating the decrease in serum potassium levels induced by β2-adrenergic agonists. Serum potassium levels should be closely monitored in hypoxic patients, in view of the possible aggravation of cardiac arrhythmias secondary to a decrease in serum potassium levels.
| 5% >, ≥0.1% | <0.1% | Incidence Unknown* | |
|---|---|---|---|
| Cardiovascular | Palpitation and tachycardia | Facial Flushing, etc | Supraventricular extrasystoles, supraventricular tachycardia, ventricular extrasystoles, atrial fibrilation, etc |
| Psychoneurologic | Tremor, headache | Dizziness, insomnia numbness of limbs, etc | Finger spasticity, muscle cramps, muscular spasm, and nervousness |
| Gastrointestinal | Nausea, vomiting. | Dry mouth, gastric discomfort, etc. | |
| Hypersensitivitynote | Skin rash, etc | Pruritus | |
| Hepatic | Increases in AST (GOT), ALT (GPT), and LDH levels and other signs of hepatic dysfunction | ||
| Other | Generalized malaize, weakness, nasal obstruction, and tinnitus | Decrease in serum potassium levels, increase of blood sugar level |
Note 1) If symptoms of hypersensitivity occur, the drug should be discontinued immediately
* The incidences of adverse reactions reported voluntarily after marketing or those reported outside Japan are not known.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
